Recent Updates
Recently added Catalysts

KAI-4729

Phase 1

Overweight or Obesity | Small Molecules | Other |Kailera Therapeutics, Inc.|Trials Updated: Nov 9, 2026

KAI-4729 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

KAI-4729 clinical trials

KAI-4729 · 1 trial · 1 indication

Phase 1 1
NCT07924761A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or OverweightOverweight or Obesity
NOT YET_RECRUITING60 Analytics
PHASE1NOT YET_RECRUITING
A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or Overweight
Overweight or Obesity
NCT0792476160
Unlock trial analytics

Study Endpoints

Primary Endpoints

Maximum Observed Plasma Concentration (Cmax) of KAI-4729 in the Upper Arm and Thigh Compared to the Abdomen
Treatment Period 1, 2 and 3: Pre-dose and up to 29 days post-dose
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-t) of KAI-4729 in the Upper Arm and Thigh Compared to the Abdomen
Treatment Period 1, 2 and 3: Pre-dose and up to 29 days post-dose
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of KAI-4729 in the Upper Arm and Thigh Compared to the Abdomen
Treatment Period 1, 2 and 3: Pre-dose and up to 29 days post-dose
Cmax of KAI-4729 in Healthy Non-Asian and Asian Participants
Treatment Period 1, 2 and 3: Pre-dose and up to 29 days post-dose; Treatment Period 1: Pre-dose and up to 29 days post-dose (Asian Participants)
AUC0-t of KAI-4729 in Healthy Non-Asian and Asian Participants
Treatment Period 1, 2 and 3: Pre-dose and up to 29 days post-dose; Treatment Period 1: Pre-dose and up to 29 days post-dose (Asian Participants)
AUC0-inf of KAI-4729 in Healthy Non-Asian and Asian Participants
Treatment Period 1, 2 and 3: Pre-dose and up to 29 days post-dose; Treatment Period 1: Pre-dose and up to 29 days post-dose (Asian Participants)

Secondary Endpoints

Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Day 1 to Day 99
Number of Participants Who Experience a Serious Adverse Event (SAE)
Day 1 to Day 99
Number of Participants Who Experience Antidrug Antibodies (ADAs) to KAI-4729
Treatment Period 1, 2 and 3: Day 1, Day 8, Day 29 post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Upper Arm Injection SiteEXPERIMENTALParticipants will receive KAI-4729 as a single SC injection into the upper arm on Day 1 of either Treatment Period 1, 2, or 3.
Abdomen Injection SiteEXPERIMENTALParticipants will receive KAI-4729 as a single SC injection into the abdomen on Day 1 of either Treatment Period 1, 2, or 3.
Thigh Injection SiteEXPERIMENTALParticipants will receive KAI-4729 as a single SC injection into the thigh on Day 1 of either Treatment Period 1, 2, or 3.
Abdomen Injection Site (Asian Participants)EXPERIMENTALAsian participants will receive KAI-4729 as a single SC injection into the abdomen on Day 1 of Treatment Period 1.

Interventions

NameTypeDescription
KAI-4729DRUGSC injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Key Inclusion Criteria: * Have a body mass index (BMI) ≥25 and ≤40 kilograms per square meter at screening (Days -28 to -2) and on Day -1 of the first Treatment Period * Non-Asian Participants Only: Be of non-Asian descent and not identify as being of East Asian origin * Asian Participants Only: Be...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 9, 2026NCT07924761NEW_TRIAL: changed
LOWNov 9, 2026NCT07924761NEW_TRIAL: changed

Explore more on BiopharmaWatch

Kailera Therapeutics, Inc. (KLRA)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with KCompanies A to ZEvery biotech and pharma company we track